Catalyst Pharmaceuticals, Inc. (CPRX): Net earnings per share growth forecast for next year

Catalyst Pharmaceuticals effectively commercializes drugs for rare brain pathologies, leveraging the success of Firdapse and Agamree. An impeccable reputation within the medical community ensures business stability. On GURU.Markets, the 12-month expected EPS growth chart is available for analysis, where 19.30 is recorded as the baseline value. A monopoly on rare disease therapies creates inertial demand, transforming the product into a high-margin asset.

For Catalyst Pharmaceuticals (CPRX), which holds the exclusive right to Firdapse within the closed-loop therapy for rare pathologies, this indicator serves as a measure of cash flow stability in the absence of market alternatives. By analyzing the trend of consensus EPS forecasts for the coming year, investors assess aggregated market expectations for net profit growth rates, which helps smooth volatility and determine the asset's fair value.